治疗良性前列腺增生药品使用情况的市场调查  

Study on the drug market of benign prostatic hyperplasia in China

作　　者：吴楠 孙健 张秋桂 孙振球[3] 

机构地区：[1]深圳南山区疾病预防控制中心,深圳518054 [2]万载县疾病预防控制中心,万载336100 [3]中南大学湘雅医学院,长沙410078

出　　处：《北方药学》2012年第9期81-82,共2页Journal of North Pharmacy

摘　　要：目的:了解中国良性前列腺增生(BPH)患者用药情况。方法:采用横断面调查的方法,对中国11个城市33个三级甲等医院门诊BPH患者用药情况进行调查。结果:5α-还原酶抑制剂非那雄胺在患者中采用百分比为最高(48.0%)。其次为-受体阻滞剂坦索罗辛(22.7%)。结论:研究结果可能会为临床BPH诊疗及治疗BPH药品的市场开发提供参考。Objective：To probe into the general information of drugs for benign prostatic hyperplasia. Methods： This cross-sectional study was performed in 33 medical centers located in 11 different cities in China. A survey investigated BPH patients who were asked to record their preferences in drugs. Results： 5-reductase inhibitor Finasteride was the most prescribed medication（48.0%）, followed by -adrenoeeptor antagonists Terazosin （22.7%）. Conclusions： The study may also provides reference for the China BPH clinical practice and the BPH drug market.

关 键 词：良性前列腺增生 药物 调查 

分 类 号：R697.3[医药卫生—泌尿科学]